Allison Petrilla

Allison Petrilla works closely with life sciences clients to design observational research studies, health economic evaluations, and market landscape assessments.

Allison has particular expertise in retrospective database analysis in both US and ex-US markets, and her work has been published across a wide range of therapeutic areas.

Prior to joining Avalere, Allison was a director of HEOR at IMS Health, focusing on retrospective study design and economic modeling for life sciences clients. She was also a health services researcher for the National Hospice and Palliative Care Organization and an HEOR consultant with ValueMedics Research.

She received an MPH with a concentration in health information systems from the George Washington University School of Public Health & Health Services in Washington, DC.

Authored Content

New Avalere analysis evaluates the trends in baseline patient characteristics among Medicare fee-for-service beneficiaries with stand-alone Part D coverage who initiated a direct oral anticoagulant during the period 2013–2017.

Avalere experts recently presented their research, “Comparison of Healthcare Utilization Among Managed Medicaid Individuals Diagnosed with Multiple Sclerosis Treated with Emergent vs. Established Disease-Modifying Therapy in the US.”

New Avalere research finds that health plan members enrolled in plans that cover abuse-deterrent formulations (ADFs) of opioids have a lower risk of opioid abuse (OA) and overdose (OD) and lower opioid abuse-related hospitalizations than people in plans that do not offer coverage of ADF opioids.